| Title: | The penetrance of rare variants in cardiomyopathy-associated genes: A cross-sectional approach to estimating penetrance for secondary findings |
| Journal: | American Journal of Human Genetics |
| Published: | 30 Aug 2023 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/37652022/ |
| DOI: | https://doi.org/10.1016/j.ajhg.2023.08.003 |
Publication 9689
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Understanding the penetrance of pathogenic variants identified as secondary findings (SFs) is of paramount importance with the growing availability of genetic testing. We estimated penetrance through large-scale analyses of individuals referred for diagnostic sequencing for hypertrophic cardiomyopathy (HCM; 10,400 affected individuals, 1,332 variants) and dilated cardiomyopathy (DCM; 2,564 affected individuals, 663 variants), using a cross-sectional approach comparing allele frequencies against reference populations (293,226 participants from UK Biobank and gnomAD). We generated updated prevalence estimates for HCM (1:543) and DCM (1:220). In aggregate, the penetrance by late adulthood of rare, pathogenic variants (23% for HCM, 35% for DCM) and likely pathogenic variants (7% for HCM, 10% for DCM) was substantial for dominant cardiomyopathy (CM). Penetrance was significantly higher for variant subgroups annotated as loss of function or ultra-rare and for males compared to females for variants in HCM-associated genes. We estimated variant-specific penetrance for 316 recurrent variants most likely to be identified as SFs (found in 51% of HCM- and 17% of DCM-affected individuals). 49 variants were observed at least ten times (14% of affected individuals) in HCM-associated genes. Median penetrance was 14.6% (±14.4% SD). We explore estimates of penetrance by age, sex, and ancestry and simulate the impact of including future cohorts. This dataset reports penetrance of individual variants at scale and will inform the management of individuals undergoing genetic screening for SFs. While most variants had low penetrance and the costs and harms of screening are unclear, some individuals with highly penetrant variants may benefit from SFs.</p>
23 Authors
- Kathryn A. McGurk
- Xiaolei Zhang
- Pantazis Theotokis
- Kate Thomson
- Andrew Harper
- Rachel J. Buchan
- Erica Mazaika
- Elizabeth Ormondroyd
- William T. Wright
- Daniela Macaya
- Chee Jian Pua
- Birgit Funke
- Daniel G. MacArthur
- Sanjay K. Prasad
- Stuart A. Cook
- Mona Allouba
- Yasmine Aguib
- Magdi H. Yacoub
- Declan P. O'Regan
- Paul J.R. Barton
- Hugh Watkins
- Leonardo Bottolo
- James S. Ware
Enabling scientific discoveries that improve human health